[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523638":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Gerhard Garhöfer, Assoc. Prof. Priv. Doz. MD","CONTACT","01 40400 29880","klin-pharmakologie@meduniwien.ac.at",[15],{"facility":5,"status":16,"city":17,"state":7,"zip":18,"country":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"RECRUITING","Vienna","1090","Austria",{"type":21,"coordinates":22},"Point",[23,24],16.37208,48.20849,{"lat":24,"lon":23},[27],{"name":28,"role":11,"phone":29,"phoneExt":7,"email":30},"Gerhard Garhöfer, Assoc. Prof. PD MD","0043 1 40400 29880","gerhard.garhoefer@meduniwien.ac.at",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Gerhard Garhofer","Principal Investigator","100523638",false,"NCT06098300","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study","Inclusion Criteria:\n\n* Men and Women aged ≥ 18 years\n* Signed informed consent\n* Apart from hypertensive retinopathy, normal ophthalmic findings\n* Non-Smokers\n* Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and\u002For diastolic office blood pressure ≥ 90 mmHg)\n* Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology\n* Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the three weeks preceding the study\n* Blood donation in the three weeks preceding the study\n* Symptoms of a clinically relevant illness in the three weeks preceding the study\n* History of family history of epilepsy\n* Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae)\n* History of hypertensive encephalopathy or intracerebral bleeding\n* Diabetes mellitus Type 1 or Type 2\n* Pregnant or breast-feeding women\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception","ALL","18 Years","90 Years",{"count":45,"type":46},30,"ESTIMATED","OBSERVATIONAL","To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.",[50,51],"Arterial Hypertension","Blood Pressure, High",[53,54,55,56,57,58,59],"Retinal Capillary Rarefaction","Hypertension","Antihypertensive medication","OCT-A","Retinal oxygen extraction","Choroidal vascularity index (CVI)","Ocular blood flow","2024-09-05",{"date":62,"type":63},"2024-09-19","ACTUAL",{"date":65,"type":63},"2023-09-01",{"date":67,"type":46},"2025-08",{"name":5,"class":6},1]